Yr Athro Gary F. Baxter
Professor of Pharmacology
Ysgol Fferylliaeth a Gwyddorau Fferyllol
- baxtergf@cardiff.ac.uk
- +44 (0)29 2068 8544
- Adeilad Redwood , Rhodfa'r Brenin Edward VII, Caerdydd, CF10 3NB
Trosolwg
Athro Ffarmacoleg ydw i sydd â diddordebau ymchwil penodol mewn clefyd a therapi cardiofasgwlaidd. Cyn hyn, roeddwn yn Rhag Is-Ganghellor Coleg y Gwyddorau Biofeddygol a Bywyd (2017-2020) ac yn Bennaeth yr Ysgol Fferylliaeth a Gwyddorau Fferyllol (2010-2017). Ar hyn o bryd, rwy'n Aelod Annibynnol (y Brifysgol) ar Fwrdd Iechyd Prifysgol Caerdydd a'r Fro.
Bywgraffiad
Graddiais mewn fferylliaeth ym Mhrifysgol Nottingham (BPharm) ac Ysbyty Brenhinol Llundain (MRPharmS). Ar ôl treulio cyfnod byr yn gwneud ymarfer clinigol mewn ysbytai yn East Anglia, gwnes i hyfforddiant ymchwil mewn ffarmacoleg arbrofol. Dyfarnwyd fy PhD yn 1992 am astudiaethau ar fodiwleiddio arrhythmia a achosir gan ischaemia ac adfer llif gwaed yn achos hypertroffedd yn y fentrigl chwith oherwydd gorbwysedd.
Gyda chefnogaeth grantiau a chymrodoriaethau’r Cyngor Ymchwil Feddygol (MRC), Ymddiriedolaeth Wellcome a Sefydliad Prydeinig y Galon, gwnes i hyfforddiant ôl-ddoethurol yng Ngholeg Prifysgol Llundain a The Cape Heart Centre, De Affrica, cyn cael fy mhenodi’n Uwch-ddarlithydd yng Ngholeg Prifysgol Llundain yn 2001. Cefais fy mhenodi'n Ddarllenydd mewn Bioleg Gardiofasgwlaidd yn y Coleg Milfeddygol Brenhinol, Prifysgol Llundain, 2002-2007. Des i i Gaerdydd yn Athro Ffarmacoleg yn 2007.
Rydw i wedi cael fy ethol i Gymrodoriaethau Cymdeithas Ffarmacolegol Prydain, y Gymdeithas Fferyllol Frenhinol, Cymdeithas y Galon yr Unol Daleithiau a Chymdeithas Cardioleg Ewrop. Cyn hynny, roeddwn yn aelod o bwyllgor ac Ysgrifennydd y Gymdeithas Brydeinig er Ymchwil Gardiofasgwlaidd, Ysgrifennydd Ewropeaidd y Gymdeithas Ryngwladol er Ymchwil y Galon, ac aelod o Nucleus a Thrysorydd Gweithgor Bioleg Celloedd y Galon Cymdeithas Cardioleg Ewrop. Rydw i wedi bod yn aelod/golygydd cysylltiol ar sawl bwrdd golygyddol gan gynnwys y British Journal of Pharmacology, Heart, Pharmacology and Therapeutics, Basic Research in Cardiology a’r Journal of Cardiovascular Pharmacology and Therapeutics.
Yn 2009, dyfarnwyd yr uwch-ddoethuriaeth (DSc) gan Brifysgol Nottingham ar gyfer corff o weithiau cyhoeddedig ar gamau amddiffynnol cyfryngwyr awtacoid mewn myocardiwm ischaemig sy’n adfer llif gwaed.
Cyhoeddiadau
2021
- Andreadou, I. et al. 2021. Influence of cardiometabolic comorbidities on myocardial function, infarction, and cardioprotection: role of cardiac redox signaling. Free Radical Biology and Medicine 166, pp. 33-52. (10.1016/j.freeradbiomed.2021.02.012)
2018
- Karwi, Q. G., Bice, J. S. and Baxter, G. F. 2018. Pre- and postconditioning the heart with hydrogen sulfide (H2S) against ischemia/reperfusion injury in vivo: a systematic review and meta-analysis. Basic Research in Cardiology 113(1), article number: 6. (10.1007/s00395-017-0664-8)
2017
- Jonas, K. C. et al. 2017. Natriuretic peptide activation of extracellular regulated kinase 1/2 (ERK1/2) pathway by particulate guanylyl cyclases in GH3 somatolactotropes. Cell and Tissue Research 369(3), pp. 567-578. (10.1007/s00441-017-2624-x)
- Karwi, Q. G. et al. 2017. Ap39, a mitochondria-targeting hydrogen sulfide (H2 s) donor, protects against myocardial reperfusion injury independently of salvage kinase signalling. British Journal of Pharmacology 174(4), pp. 287-301. (10.1111/bph.13688)
2016
- Karwi, Q. G., Whiteman, M., Wood, M. E., Torregrossa, R. and Baxter, G. F. 2016. Pharmacological postconditioning against myocardial infarction with a slow-releasing hydrogen sulfide donor, GYY4137. Pharmacological Research 111, pp. 442-451. (10.1016/j.phrs.2016.06.028)
- Bice, J. S., Jones, B. R., Chamberlain, G. R. and Baxter, G. F. 2016. Nitric oxide treatments as adjuncts to reperfusion in acute myocardial infarction: a systematic review of experimental and clinical studies. Basic Research in Cardiology 111(2), article number: 23. (10.1007/s00395-016-0540-y)
2015
- Bice, J. S. and Baxter, G. F. 2015. Postconditioning signalling in the heart: mechanisms and translatability. British Journal of Pharmacology 172(8), pp. 1933-1946. (10.1111/bph.12976)
2014
- Ferdinandy, P., Hausenloy, D. J., Heusch, G., Baxter, G. F. and Schulz, R. 2014. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacological Reviews 66(4), pp. 1142-1174. (10.1124/pr.113.008300)
- Bice, J. S., Burley, D. and Baxter, G. F. 2014. Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic muanosine monophosphate manipulation. Journal of Cardiovascular Pharmacology and Therapeutics 19(3), pp. 269-282. (10.1177/1074248413518971)
- Bice, J. S., Keim, Y., Stasch, J. and Baxter, G. F. 2014. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size. Cardiovascular Research 101(2), pp. 220-228. (10.1093/cvr/cvt257)
- Thompson, I. R. et al. 2014. Homologous and heterologous desensitization of guanylyl cyclase-B signaling in GH3 somatolactotropes. Cell and Tissue Research 355(2), pp. 425-436. (10.1007/s00441-013-1763-y)
- Burley, D., Cox, C. D., Zhang, J., Wann, K. T. and Baxter, G. F. 2014. Natriuretic peptides modulate ATP-sensitive K+ channels in rat ventricular cardiomyocytes. Basic Research in Cardiology 109, article number: 402. (10.1007/s00395-014-0402-4)
2012
- Burley, D. S., Cox, C. D., Wann, K. T. and Baxter, G. F. 2012. P541: Natriuretic peptide inhibition of sarcolemmal atp-sensitive potassium channel in rat cardiomyocytes [Abstract]. Cardiovascular Research 93(S1), pp. S105-S106. (10.1093/cvr/cvr336)
2010
- Ovize, M. et al. 2010. Postconditioning and protection from reperfusion injury: where do we stand? Position Paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovascular Research 87(3), pp. 406-423. (10.1093/cvr/cvq129)
- Elsey, D., Fowkes, R. C. and Baxter, G. F. 2010. L-cysteine stimulates hydrogen sulfide synthesis in myocardium associated with attenuation of ischemia-reperfusion injury. Journal of Cardiovascular Pharmacology and Therapeutics 15(1), pp. 53-59. (10.1177/1074248409357743)
- Hamid, S. A., Totzeck, M., Drexhage, C., Thompson, I., Fowkes, R. C., Rassaf, T. and Baxter, G. F. 2010. Nitric oxide/cGMP signalling mediates the cardioprotective action of adrenomedullin in reperfused myocardium. Basic Research in Cardiology 105(2), pp. 257-266. (10.1007/s00395-009-0058-7)
- Elsey, D., Fowkes, R. C. and Baxter, G. F. 2010. Regulation of cardiovascular cell function by hydrogen sulfide (H2S). Cell Biochemistry and Function 28(2), pp. 95-106. (10.1002/cbf.1618)
- Gorbe, A., Giricz, Z., Szunyog, A., Csont, T., Burley, D. S., Baxter, G. F. and Ferdinandy, P. 2010. Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. Basic Research in Cardiology 105(5), pp. 643-650. (10.1007/s00395-010-0097-0)
- Hausenloy, D. J. et al. 2010. Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Research in Cardiology 105(6), pp. 677-686. (10.1007/s00395-010-0121-4)
- Rautureau, Y., Gowers, I., Wheeler-Jones, C. P. D. and Baxter, G. F. 2010. C-type natriuretic peptide regulation of guanosine-3′,5′-cyclic monophosphate production in human endothelial cells. Autonomic and Autacoid Pharmacology 30(3), pp. 185-192. (10.1111/j.1474-8673.2009.00449.x)
2009
- Giricz, Z., Gorbe, A., Pipis, J., Burley, D. S., Ferdinandy, P. and Baxter, G. F. 2009. Hyperlipidaemia induced by a high-cholesterol diet leads to the deterioration of guanosine-3',5'-cyclic monophosphate/protein kinase G-dependent cardioprotection in rats. British Journal of Pharmacology 158(6), pp. 1495-1502. (10.1111/j.1476-5381.2009.00424.x)
- Burley, D. S. and Baxter, G. F. 2009. Pharmacological targets revealed by myocardial postconditioning. Current Opinion in Pharmacology 9(2), pp. 177-188. (10.1016/j.coph.2008.11.009)
2008
- Burley, D., George, C., Wann, K. T. and Baxter, G. 2008. Evidence for serca and BKCa activation in BNP protection of reperfused myocardium [Abstract]. Journal of Molecular and Cellular Cardiology 44(4), pp. 717. (10.1016/j.yjmcc.2008.02.015)
- Gorbe, A., Giricz, Z., Szunyog, A., Baxter, G. F., Csont, T. and Ferdinandy, P. 2008. Role of NO-cGMP-PKG signalling in the protection of cardiac myocytes subjected to hypoxia/reoxygenation [Abstract]. Journal of Molecular and Cellular Cardiology 44(4), pp. 808., article number: 231. (10.1016/j.yjmcc.2008.02.232)
- Kleinz, M. J. and Baxter, G. F. 2008. Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase. Regulatory Peptides 146(1-3), pp. 271-277. (10.1016/j.regpep.2007.10.002)
- Baxter, G. F. and Burley, D. S. 2008. Reperfusion and calculated RISKs: pharmacological postconditioning of human myocardium. British Journal of Pharmacology 153(1), pp. 1-3. (10.1038/sj.bjp.0707498)
- Hamid, S. A., Davidson, S. M., Burley, D. S., Yellon, D. M. and Baxter, G. F. 2008. Rho-kinase mediates reoxygenation-induced cardiomyocyte death and promotes mitochondrial transition pore opening. Journal of Molecular and Cellular Cardiology 44(4), pp. 791-792.
2007
- Burley, D. S. and Baxter, G. F. 2007. Activation of particulate guanylate cyclase during early reperfusion limits infarct size in the rat isolated heart. Journal of Molecular and Cellular Cardiology 42(6(S)), pp. S209. (10.1016/j.yjmcc.2007.03.633)
- Elsey, D., Fowkes, R. C. and Baxter, G. F. 2007. H2S production in myocardial ischaemia and reperfusion. Journal of Molecular and Cellular Cardiology 42(6), pp. S197-S198. (10.1016/j.yjmcc.2007.03.600)
- Giricz, Z., Burley, D. S., Ferdinandy, P. and Baxter, G. F. 2007. Activation of cyclic GMP/PKG pathway fails to limit infarct size in hearts from hyperlipidaemic rats. Journal of Molecular and Cellular Cardiology 42(6), pp. S214-S214. (10.1016/j.yjmcc.2007.03.647)
- Gorbe, A., Giricz, Z., Huliak, I., Baxter, G. F. and Ferdinandy, P. 2007. NO-cGMP-PKG signalling pathway involved in the protection of cardiac myocytes during hypoxia/reoxygenation. Journal of Molecular and Cellular Cardiology 42(6(S1)), pp. 48-S49. (10.1016/j.yjmcc.2007.03.137)
- Hamid, S. A., Totzeck, M., Drexhage, C., Thompson, I., Fowkes, R. C., Rassaf, T. and Baxter, G. F. 2007. NO/cGMP pathway in adrenomedullin mediated cardioprotection in mouse. Journal of Molecular and Cellular Cardiology 42(6), pp. S195. (10.1016/j.yjmcc.2007.03.592)
- Kleinz, M. J. and Baxter, G. F. 2007. Apelin reduces myocardial reperfusion injury independent of PI3K/Akt and P70S6K [Abstract]. Journal of Molecular and Cellular Cardiology 42(6, S1), pp. S203. (10.1016/j.yjmcc.2007.03.616)
- Baxter, G. F., Bower, H. and Hamid, S. 2007. Rho-kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. American Journal of Physiology - Heart and Circulatory Physiology 292(6), pp. H2598-H2606. (10.1152/ajpheart.01393.2006)
- Burley, D. S. and Baxter, G. F. 2007. B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Research in Cardiology 102(6), pp. 529-541. (10.1007/s00395-007-0672-1)
- Burley, D. S., Ferdinandy, P. and Baxter, G. F. 2007. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. British Journal of Pharmacology 152(6), pp. 855-869. (10.1038/sj.bjp.0707409)
- Burley, D. S., Hamid, S. A. and Baxter, G. F. 2007. Cardioprotective actions of peptide hormones in myocardial ischemia. Hear Failure Reviews 12(3-4), pp. 279-291. (10.1007/s10741-007-9029-y)
- Ebrahim, Z., Yellon, D. M. and Baxter, G. F. 2007. Attenuated cardioprotective response to bradykinin, but not classical ischaemic preconditioning, in DOCA-salt hypertensive left ventricular hypertrophy. Pharmacological Research 55(1), pp. 42-48. (10.1016/j.phrs.2006.10.004)
- Ebrahim, Z., Yellon, D. M. and Baxter, G. F. 2007. Ischemic preconditioning is lost in aging hypertensive rat heart: Independent effects of aging and longstanding hypertension. Experimental Gerontology 42(8), pp. 807-814. (10.1016/j.exger.2007.04.005)
- Ferdinandy, P., Schulz, R. and Baxter, G. F. 2007. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacological Reviews 59(4), pp. 418-458. (10.1124/pr.107.06002)
- Hamid, S. A., Bower, H. S. and Baxter, G. F. 2007. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. American Journal of Physiology - Heart and Circulatory Physiology 292(6), pp. H2598-H2606. (10.1152/ajpheart.01393.2006)
2003
- Baxter, G. F., Kis, A. and Yellon, D. 2003. Second window of protection following myocardial preconditioning: an essential role of PI3 kinase and p70S6 kinase. Journal of Molecular and Cellular Cardiology 35(9), pp. 1063-1071. (10.1016/S0022-2828(03)00208-6)
- D'Souza, S. P. et al. 2003. B-type natriuretic peptide limits infarct size in rat isolated heart via KATP channel opening. American Journal of Physiology - Heart and Circulatory Physiology 284(5), pp. H1592-H1600. (10.1152/ajpheart.00902.2002)
- Baxter, G. F., Kis, A. and Yellon, D. 2003. Role of nuclear factor-kB activation in acute ischaemia-reperfusion injury in myocardium. British Journal of Pharmacology 138(5), pp. 894-900. (10.1038/sj.bjp.0705108)
Addysgu
Rwy'n cynnig goruchwyliaeth ar gyfer traethodau hir, tiwtorialau a prosiectau israddedig yn y rhaglen MPharm. Mae gen i brofiad helaeth o gynllunio, adolygu, cymeradwyo ac asesu’r cwricwlwm yng Nghaerdydd a sefydliadau allanol.
Ers sawl degawd, mae clefyd ischaemig y galon wedi bod yn un o brif achosion morbidrwydd a marwolaethau yn y gwledydd diwydiannol. Er bod tueddiadau yn y DU ac UDA tuag at ostyngiad yn nifer y marwolaethau o ganlyniad i glefyd ischaemig y galon, rhagwelir mai'r cyflwr hwn fydd prif achos marwolaeth ledled y byd erbyn 2030, gan fod yn fwy na nifer y marwolaethau oherwydd clefydau heintus neu neoblastig. Felly, mae clefyd ischaemig y galon yn her feddygol a gwyddonol sylweddol a pharhaus.
Diddordebau ymchwil
- Bioleg fasgwlaidd fyocardiaidd a choronaidd, gyda phwyslais arbennig ar bathoffisioleg cnawdnychiad myocardiaidd acíwt
- Seiliau cellog anaf adfer llif y gwaed yn sgîl ischaemia, a mecanweithiau amddiffyn y galon
Goruchwylio ymchwil ddiweddar, (myfyrwyr PhD, cydymdeithion ôl-ddoethurol ac ysgolheigion sy'n ymweld)
Dmitra Andreou (Ysgolhaig Erasmus, Prifysgol Athen, 2011)
Meropi Mastropetrou (Ysgolhaig Erasmus, Prifysgol Athen, 2015-2016)
Abbes Cadi-Tazi (Ysgolhaig Erasmus, Prifysgol Grenoble, 2012)
Paolo Strazzacappa (Ysgolhaig Erasmus, Prifysgol Padova, 2009-2010)
Cyrff ariannu sy'n cefnogi ein gwaith
Sefydliad Prydeinig y Galon
Y Cyngor Ymchwil Feddygol
Ymchwil y Galon y DU
Ymddiriedolaeth Wellcome
